Morinaga Milk Obtains the Registration of "New Food Ingredient" in China for Use of Its Probiotic Bifidobacterium longum BB536 in Infant and Toddler Foods
Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy product company, today announced its proprietary probiotic Bifidobacterium longum BB536 was approved by the National Health Commission (NHC) of the People’s Republic of China as a new food ingredient for use in infant and toddler foods (under the age of three) on 11th May 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517005112/en/
Morinaga Milk obtains the registration of "New Food Ingredient" in China for use of its probiotic Bifidobacterium longum BB536 in infant and toddler foods on 11th May 2022. (Graphic: Business Wire)
Following a complex and lengthy registration process, the probiotic strain B. longum BB536 meets the highest standards of safety and regulatory compliance and has now completed the approval process for use as an ingredient in infant and toddler milk and food products for children under three years old in China.
“We are extremely proud to have achieved the registration process and consider it an endorsement of the core values of Morinaga Milk’s HRB (human-residential bifidobacteria),” said Dr. Xiao, General Manager of Next Generation Science Institute of Morinaga Milk. “We believe the highest safety standards that we uphold and the strong scientific evidence behind BB536 are what brought us come this far. It has been a long registration process and this approval is an incredible regulatory achievement given the limited number of strains that made it to the list of only 14 strains, including BB536,” he added.
Stringent safety requirements
The “New Food Ingredient” is a regulatory system required for food ingredients to be specifically permitted for use in general foods and infant and toddler foods (<3 years) in China. The registered ingredient must meet certain requirements in terms of nutrition, health, and safety and comply with the regulatory standards in China. To date, there are only 13 registered probiotic strains that can be used in infant and toddler foods in China (six strains in 2011, three in 2016, three in 2020, and one in 2021). The company’s flagship strain, B. longum BB536, is a new addition to the positive list.
Morinaga Milk is the only Japanese company to have obtained the registration for probiotic strains. B. longum BB536 is the company’s second strain to have obtained the approval, following B. breve M-16V in 2016. The company focuses on human-residential bifidobacteria (HRB) – the natural inhabitants of the human gut that exhibit numerous superior physiological functions. Morinaga Milk is committed to develop high quality, safe, reliable and natural probiotics over the past decades and is some way ahead of the curve in HRB research. Both BB536 and M-16V approved by the China’s NHC are the HRB strains.
“The registration process is hard and it should be because the ingredient is dedicated for a vulnerable population. There were some changes in the regulatory frameworks and the safety requirements have become more stringent,” said Dr. Xiao. “However, along with an exceptionally long history of safe use in humans, including infants and young children, the safety and efficacy of BB536 continues to be undoubtedly proven through solid science, leading to the acknowledgement by the China’s NHC,” he added.
All set for use in infant and toddler milk
The Chinese infant and toddler milk market has tripled in size in the 10 years between 2010 and 2019, and is expected to be worth $24.4 billion in 2020, accounting for 47% of the global market (Euromonitor International "Milk Formula in China", September 2021). In addition, the market for infant and toddler milk containing the probiotics Bifidobacterium strain has been on the rise in recent years (Research by Morinaga Milk Industry Co., Ltd. using Mintel GNPD, November 2021).
Under the Morinaga Milk Group's 10-Year Vision, the company aims to achieve a global business sales ratio of 15% or more by the fiscal year ending March 2029. The company is eyeing the giant infant and toddler milk market in China and aims to strengthen its sales in China to help achieve the goal.
Morinaga Milk’s B. longum BB536 has received the FDA GRAS notification in US for use in conventional foods (GRAS Notice No. GRN 000268) and infant and toddler milk (GRAS Notice No. GRN 000877). It has been incorporated in various products worldwide for more than 50 years. Affirmation of this newest registration in China adds value to the company’s proprietary probiotic strain, diversifying its application options available in the infant category.
First B. longum subsp. longum strain in the approval list
Bifidobacterium longum BB536 is a clinically effective, well-established, multifunctional probiotic strain that has a long history of human use (supported by more than 220 scientific studies (as of March 2022)). For half a century, B. longum BB536 has been the superior Human-Residential Bifidobacteria (HRB) probiotic strain that provides a consistent beneficial effect in maintaining human health. Already well known as a leading functional probiotic ingredient for application in food and dietary supplements, Morinaga Milk’s B. longum BB536 is now expanding its application opportunities into the new space, to be specifically permitted for use in infant and toddler milk and foods in China.
“We have always been researching on bifidobacteria, particularly those that naturally occur in the human gut, which are known as the HRB strains,” Dr. Fumiaki Abe, Director of Research and Development Institute of Morinaga Milk. “We obtained the approval for our first HRB strain, B. breve M-16V in 2016, and we are extremely delighted that BB536 has now also passed the stringent process to obtain the Chinese approval pertaining to infant and toddler foods.” “BB536 is the first B. longum subsp. longum strain of HRB in the positive list and its potential is very much exciting,” he added.
Pioneering in bifidobacteria research
Morinaga Milk Industry Co., Ltd. is one of the leading dairy product companies in Japan with a century of history harnessing the nutritional properties of dairy products and its functional ingredients. Morinaga Milk is also a key global probiotics manufacturer that excels in innovative technology and offers a premium line of probiotics and functional ingredients worldwide. Since the 1960s, Morinaga Milk has been engaged in research on the safety, functional health benefits, and mechanisms of action of probiotic bifidobacteria to better understand their role in maintaining human health. For more information about Morinaga Human-Residential Bifidobacteria (HRB) probiotics, please visit us at https://morinagamilk-ingredients.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Morinaga Milk Industry Co., Ltd.
Investor& Public Relations Department
Mitsunori Watanabe / Kazuaki Kajikawa
Junichi Minami / Chyn Boon Wong
Morinaga Milk website: https://www.morinagamilk.co.jp/english/
Morinaga Probiotics Center website: https://morinagamilk-ingredients.com/
Morinaga Probiotics Center LinkedIn: https://www.linkedin.com/company/morinaga-probiotics-center
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Positive Results of EfficAPSI Real-World Study Confirm Significant Benefit of Sublingual Liquid AIT Treatment on the Onset and Worsening of Asthma in Patients With Allergic Rhinitis2.7.2022 15:08:00 CEST | Press release
Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), today announced positive data from its EfficAPSI real-world study. Presented at the 2022 European Academy of Allergy and Clinical Immunology (EAACI) congress in Prague (Czech Republic), the real-world study confirmed significant benefit of sublingual liquid allergen immunotherapy treatment (AIT) on the onset and worsening of asthma in patients with allergic rhinitis. The retrospective longitudinal pharmaco-epidemiological real-world study included over 430,000 patients: more than 100,000 patients with allergic rhinitis with or without asthma treated with sublingual liquid immunotherapy and symptomatic drugs; compared to more than 330,000 patients with allergic rhinitis with or without asthma treated with symptomatic drugs only. The primary objective of the study was the evaluation of the impact of sublingual liquid AIT on the onset and worsening of asthma in patients with allergic rhinitis. St
Boyd Acquires Sensata’s Thermal Test and Controls Business1.7.2022 17:29:00 CEST | Press release
Boyd, a world-leading innovator of technologies in engineered materials and thermal management, announced it acquired Sensata’s Thermal Test and Controls Business (NYSE:ST). This business specializes in the design and manufacturing of advanced thermal control systems, adapters, and sockets critical to the thermal test process for high-end logic and memory semiconductors. With a long history of serving leading global semiconductor companies, the addition complements Boyd’s existing thermal business, which includes air and liquid cooled thermal management technologies. Boyd designs and manufactures complex thermal solutions for high-performance semiconductors used in applications such as 5G, hyperscale data center, eMobility, and artificial intelligence. With this acquisition, Boyd expands its offering to current semiconductor customers by adding advanced controls and thermal test systems essential to the production of high-end memory and logic devices. “This acquisition is a natural fit
IFF Completed Divestiture of Microbial Control Business1.7.2022 15:45:00 CEST | Press release
IFF (NYSE:IFF) today announced that it has successfully completed the previously announced divestiture of its Microbial Control business unit to LANXESS. Welcome to IFF At IFF (NYSE: IFF), an industry leader in food, beverage, health, biosciences and scent, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet.Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn. © 2022 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20220630005790/en/Contact information Michael DeVeau Chief Investor Relations
Digi International Unveils Digi XBee LR Module for LoRaWAN Connectivity for IoT Deployments1.7.2022 15:00:00 CEST | Press release
Digi International®, (NASDAQ: DGII), a leading global provider of Internet of Things (IoT) connectivity products, solutions, and services, today unveiled the Digi XBee® LR, the first XBee-class pre-integrated and pre-certified wireless communication module for sensors and end-nodes using LoRaWAN. Coupled with the rich connectivity, device and gateway management capabilities of Digi X-ON™—its Low-Power Wide Area (LPWA) IoT data cloud platform—Digi provides a complete IoT solution with automated provisioning and deployment to help enterprises achieve significant ROI and faster market access. The Digi XBee LR module brings a new connectivity option to one of the most widely adopted wireless IoT module footprints, with more than 20 million devices deployed. This fully developed, tested, and certified module gives OEMs the freedom to create innovative public- or private-cloud solutions for organizations in agriculture, energy, logistics, manufacturing, utilities, and other sectors. These ap
Juniper Networks Announces Cloud Metro Innovation to Drive Sustainable Business Growth for Service Providers1.7.2022 14:35:00 CEST | Press release
Juniper Networks (NYSE: JNPR), a leader in secure, AI-driven networks, today announced the innovation that will power its vision and strategy for Cloud Metro – a new category of solutions for service providers, optimized for metro transformation and sustainable business growth. Traditional “retro” metro networks are device-centric and are buckling under the extreme scale, agility and experience demands that widespread digital transformation and the advent of 5G services are bringing. Today’s announcement focuses on enabling sustainable business growth, with a series of high-performance networking systems, powered by AI-enabled, cloud-delivered automation, specifically designed to build next generation Cloud Metro infrastructure. These systems will deliver significantly-reduced natural resource consumption capabilities to help sustain the planet, improved tools and simplified working methods to help sustain over-pressured operations teams, along with embedded service assurance and secur